NFKB1 and liver cancer: Compared to the TAE group, we observed that the expression of NF-κB was significantly decreased in the cancerous tissues of the combined treatment group, thus we speculate that PPAR-α agonist WY-14643 has an inhibitory effect on liver cancer following TAE.